Early Phase Clinical Trials 2014
Larger, longer grants (up to $1.5m for up to 4 years) for projects focusing on Phase I or IIa clinical trials.
Targeted Diseases: FTD & PSP 2014
The goal of the Targeted Diseases program is to provide targeted support for high impact, translational research in frontotemporal dementia (FTD) and progressive supranuclear palsy (PSP).
Biomarkers Against Neurodegenerative Diseases 2015 | 2013
The main objective of BAND is to stimulate analyses across Alzheimer’s disease (AD), Parkinson’s disease (PD), and other neurodegenerative diseases to increase understanding of pathogenesis similarities and differences. Applicants may request funding for up to two years and $150,000 in total costs.
Mechanisms of Cellular Death in Neurodegeneration 2014
The MCDN Initiative invites research proposals that will explore brain cell death mechanisms in neurodegenerative diseases. MCDN funds either a consortium of investigative teams or individual team-based projects ranging between USD$100,000-$1,250,000.
The W. Garfield Weston Foundation – Alzheimer’s Drug Discovery Foundation (ADDF) – Canada 2011
Three-year grant to support clinical trials for Alzheimer’s therapeutics through the ADDF-Canada’s Program to Accelerate Clinical Trials (PACT). Download Press Release
The W. Garfield Weston Foundation – Brain Canada Foundation Multi-Investigator Research Initiative (MIRI) 2011
Three-year team based grants for transformative grants for research aimed at improving our understanding of human nervous system function and dysfunction and its impact on health. Download Press Release
The W. Garfield Weston Foundation – Michael J. Fox Foundation 2011
Funding for 9 teams across Canada working on promising treatments for Parkinson’s disease.